Category H Profitability Analysis

Category H Profitability Analysis

There has been a lot of discussion about Category H at recent events, online and on socials. Charles Joynson, WaveData MD, poses the question; ‘Will it cut another group of generics to the bone and seriously damage pharmacy and supplier profitability? Or will it...
Are Parallel Imports Profitable for Pharmacies?

Are Parallel Imports Profitable for Pharmacies?

We know that pharmacies buying generics are making a loss when they dispense. Previous analysis, available on the Wavedata.co.uk articles page, shows that over 1200 generic products each month are unprofitable. However, what about parallel imports, are they profitable...
Medicine Matters Podcast Episode 6

Medicine Matters Podcast Episode 6

Charles Joynson, WaveData MD, was delighted to join Jeremy Durrant, Director of Communications and External Engagement at Medicines UK, in the latest episode of their podcast Medicine Matters. It’s a lively discussion, looking at pricing trends over the last 12...
Generic Market Prices versus the Drug Tariff

Generic Market Prices versus the Drug Tariff

To start the year off with a bang, we thought we’d compare the generic product prices we get from our Pharmacy and Dispensing Doctor data suppliers with the Drug Tariff for each product. This obviously excludes some products where there is no Drug Tariff...
A look back at NHS Reorganisations

A look back at NHS Reorganisations

At last week’s EMIG Quarterly meeting Donal Markey, Assistant director of Programmes, Transformation and Performance, said that the Irish health service had been reorganised just once while England’s NHS had been reorganised 7 times. As we are in our Silver...
When does unprofitability turn into a serious shortage?

When does unprofitability turn into a serious shortage?

Four times over the last 10 years, free market competition between the manufacturers of Olanzapine tablets drove the price to a level where profit was impossible and withdrawal is the only option. When prices decline in the market, the reimbursement drug tariff often...